Wai Yuen Tong Medicine Holdings Limited (HKG:0897)
0.3200
+0.0200 (6.67%)
Jul 31, 2026, 3:51 PM HKT
HKG:0897 Revenue
In the fiscal year ending March 31, 2026, Wai Yuen Tong Medicine Holdings had annual revenue of 683.44M HKD, down -8.30%. Wai Yuen Tong Medicine Holdings had revenue of 360.63M in the half year ending March 31, 2026.
Revenue
683.44M
Revenue Growth
-8.30%
P/S Ratio
0.52
Revenue / Employee
989.06K
Employees
691
Market Cap
356.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 683.44M | -61.86M | -8.30% |
| Mar 31, 2025 | 745.30M | -38.58M | -4.92% |
| Mar 31, 2024 | 783.88M | 60.28M | 8.33% |
| Mar 31, 2023 | 723.60M | -667.81M | -48.00% |
| Mar 31, 2022 | 1.39B | 282.85M | 25.51% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 1.93B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.08B |
| Kontafarma China Holdings | 914.71M |
| PuraPharm Corporation | 336.11M |
| Tianda Pharmaceuticals | 322.95M |
| Fusen Pharmaceutical Company | 304.20M |
| Pak Fah Yeow International | 214.28M |